Company Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers.
It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers.
Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer.
The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
| Country | United States |
| Founded | 2014 |
| IPO Date | Dec 19, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Chandler Robinson |
Contact Details
Address: 1000 Skokie Boulevard, Suite 350 Wilmette, Illinois 60091 United States | |
| Phone | 847 388 0349 |
| Website | monopartx.com |
Stock Details
| Ticker Symbol | MNPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001645469 |
| CUSIP Number | 61023L108 |
| ISIN Number | US61023L1089 |
| Employer ID | 32-0463781 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Christopher M. Starr Ph.D. | Co-Founder and Independent Executive Chairman of the Board |
| Andrew J. Cittadine M.B.A. | Chief Operating Officer |
| Karthik Radhakrishnan CFA | Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer |
| Dr. Patrice P. Rioux M.D., Ph.D. | Acting Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 424B3 | Prospectus |
| Dec 17, 2024 | EFFECT | Notice of Effectiveness |
| Dec 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 30, 2024 | 8-K | Current Report |